Mind Medicine Inc - Ordinary Shares (Sub Voting) Stock

$7.57

0.07% yesterday

Nasdaq, Nov 25, 09:49 pm CET

ISIN

CA60255C1095

Symbol

MNMD

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Mind Medicine Inc - Ordinary Shares (Sub Voting) Stock price

$7.61

+1.89 32.95% 5Y

Nasdaq, Closing price Mon, Nov 25 2024

+0.05 0.66%

ISIN

CA60255C1095

Symbol

MNMD

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$214.32m
Enterprise Value	$-56.65m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	0.77
P/B ratio (TTM) P/B ratio	2.37
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-93.66m
Free Cash Flow (TTM) Free Cash Flow	$-73.36m
Cash position	$295.28m
EPS (TTM) EPS	$-2.09
P/E forward	negative
Short interest	13.63%

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Get Started for Free Today

Mind Medicine Inc - Ordinary Shares (Sub Voting) Stock Analysis

Unlock Scores for Free

??

8 Analysts have issued a Mind Medicine Inc - Ordinary Shares (Sub Voting) forecast:

8x Buy

100%

More details on Analyst Estimates Including Price Targets

8 Analysts have issued a Mind Medicine Inc - Ordinary Shares (Sub Voting) forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Mind Medicine Inc - Ordinary Shares (Sub Voting)

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	- -	- 100%
- Direct Costs	1.32 1.32	59% 59% -
Gross Profit	-1.32 -1.32	59% 59% -
- Selling and Administrative Expenses	37 37	13% 13% -
- Research and Development Expense	54 54	16% 16% -
EBITDA	-92 -92	12% 12% -
- Depreciation and Amortization	1.32 1.32	59% 59% -
EBIT (Operating Income) EBIT	-94 -94	9% 9% -
Net Profit	-98 -98	27% 27% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Mind Medicine Inc - Ordinary Shares (Sub Voting) Stock News

Neutral

Business Wire

●

8 days ago

MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Gregg A. Pratt, Ph.D., as Chief Regulatory and Quality Assurance Officer. Dr. Pratt will serve as a member of the Executive Committee and oversee th...

Neutral

Business Wire

●

13 days ago

MindMed to Participate in Upcoming Investor Conferences

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company's management team will participate in the following investor conferences: Jefferies London Healthcare Conference Format: 1x1 Meetings Dates:...

Positive

Proactive Investors

●

14 days ago

RFK Jr's appointment in health could accelerate psychedelic drug development, analysts say

President-elect Donald Trump's promise that Robert F Kennedy Junior (RFK Jr) will take on a “big role” in shaping health policy could be a positive for psychedelics given RKF Jr's well-documented support of this drug class, analysts at Jefferies believe. “RFK Jr seems positively inclined and sounds motivated to help foster psychedelic drug development,” analysts wrote in a note to clients, noti...

More Mind Medicine Inc - Ordinary Shares (Sub Voting) News

Company Profile

Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The firm develops a non-hallucinogenic version of the psychedelic ibogaine. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn in 2019 and is headquarter in New York, NY.

Head office	Canada
CEO	Robert Barrow
Employees	57
Founded	2019
Website	www.mindmed.co

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now